IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: None known. WARNINGS and PRECAUTIONS — Risks Associated With Exercise or Pharmacologic Stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, and bronchoconstriction, as well as cerebrovascular reactions such as headache, paraesthesias, convulsions, somnolence and cerebrovascular accident, including hemorrhage. Perform stress testing in a setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information.
Please see Indications and additional Important Safety Information below.
Image earlier with Myoview
Myoview is the only FDA-approved myocardial perfusion imaging agent that can begin gathering diagnostic information about your patient’s heart in as soon as 15 minutes1
Experience the potential benefits of Myoview
For Healthcare Providers: Diagnostic Confidence and Practice Efficiencies
- High-quality imaging done fast (as early as 15 minutes post-injection , per package insert)1
- Higher patient throughput and flexibility, which may ultimately support increased departmental productivity & efficiency3
- Myoview may reduce the need for rescans3
For Patients: Enhanced Experience
- Lower dose range helps minimize patient radiation exposure
o Myoview offers an approved dose range with the lowest dose (5-12 mCi and 15-33 mCi) available for MPI agents2 (See Full Prescribing Information for Myoview for the recommended dosing)
- Patient friendly
o Myoview’s 15-minute start time to image acquisition enables efficient protocol for stress and rest imaging, and reduces patient waiting time
1. Myoview [prescribing information]. Arlington Heights, IL: GE Healthcare; 2017.
2. NIH-NHLBI/NCI, National Institutes of Health-National Heart, Lung, and Blood Institute/National Cancer Institute. https://www.nih.gov/.
Accessed February 13, 2018.
3. Ravizzini GC, Hanson MW, Shaw LK, et al. Efficiency comparison between 99mTc-tetrofosmin and 99mTc-sestamibi myocardial perfusion studies. Nucl Med Comm. 2002;23(3):203-208.